Stephen Ansell

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. doi Hodgkin lymphoma: 2012 update on diagnosis, risk-stratification, and management
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Hematol 87:1096-103. 2012
  2. pmc Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma
    S M Ansell
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 26:1046-52. 2012
  3. doi Annual clinical updates in hematological malignancies: a continuing medical education series. Hodgkin lymphoma: 2011 update on diagnosis, risk-stratification, and management
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 86:851-8. 2011
  4. pmc Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 85:824-33. 2010
  5. pmc Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Lancet Oncol 12:361-8. 2011
  6. ncbi Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma
    S M Ansell
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Leukemia 18:616-23. 2004
  7. ncbi Non-Hodgkin lymphoma: diagnosis and treatment
    Stephen M Ansell
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mayo Clin Proc 80:1087-97. 2005
  8. doi Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells
    Stephen M Ansell
    Mayo Clinic, Division of Hematology, 200 First Street SW, Rochester, MN 55905, USA
    Expert Opin Investig Drugs 20:99-105. 2011
  9. pmc Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma
    Stephen M Ansell
    Division of Hematology and Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Cancer Res 15:6446-53. 2009
  10. pmc Serum BLyS levels increase after rituximab as initial therapy in patients with follicular Grade 1 non-Hodgkin lymphoma
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 84:71-3. 2009

Detail Information

Publications84

  1. doi Hodgkin lymphoma: 2012 update on diagnosis, risk-stratification, and management
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Hematol 87:1096-103. 2012
    ..Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 9,000 new patients annually and representing approximately 11% of all lymphomas in the United States...
  2. pmc Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma
    S M Ansell
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 26:1046-52. 2012
    ....
  3. doi Annual clinical updates in hematological malignancies: a continuing medical education series. Hodgkin lymphoma: 2011 update on diagnosis, risk-stratification, and management
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 86:851-8. 2011
    ..For patients who fail HDCT with ASCT, palliative chemotherapy, nonmyeloablative allogeneic transplant, or participation in a clinical trial should be considered...
  4. pmc Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 85:824-33. 2010
    ..Autologous stem cell transplant should be considered in all eligible patients with relapsed disease...
  5. pmc Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Lancet Oncol 12:361-8. 2011
    ..We therefore tested its efficacy and toxicity in combination with rituximab (an antiCD20 antibody) in patients with relapsed or refractory mantle cell lymphoma...
  6. ncbi Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma
    S M Ansell
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Leukemia 18:616-23. 2004
    ..We conclude that inhibition of survivin expression is an attractive therapeutic strategy in aggressive non-Hodgkin's lymphomas, and that combining survivin ASO with rituximab may enhance the efficacy of this approach...
  7. ncbi Non-Hodgkin lymphoma: diagnosis and treatment
    Stephen M Ansell
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mayo Clin Proc 80:1087-97. 2005
    ..Patients with chemoresistant disease or whose disease relapses subsequently should be treated with novel experimental therapies...
  8. doi Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells
    Stephen M Ansell
    Mayo Clinic, Division of Hematology, 200 First Street SW, Rochester, MN 55905, USA
    Expert Opin Investig Drugs 20:99-105. 2011
    ..Patients with these histologies who subsequently progress after salvage chemotherapy and autologous stem cell transplantation (ASCT) have very limited treatment options and are in need of novel effective therapies...
  9. pmc Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma
    Stephen M Ansell
    Division of Hematology and Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Cancer Res 15:6446-53. 2009
    ..Blocking anti-CTLA-4 monoclonal antibodies improves host resistance to immunogenic tumors, and the anti-CTLA-4 antibody ipilimumab (MDX-010) has clinical activity against melanoma, prostate, and ovarian cancers...
  10. pmc Serum BLyS levels increase after rituximab as initial therapy in patients with follicular Grade 1 non-Hodgkin lymphoma
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 84:71-3. 2009
    ..A significant increase was seen in the serum levels of BLyS (P = 0.0001) after rituximab therapy. The increase was independent of genetic variability in the BLyS gene...
  11. ncbi Antibody therapy for non-Hodgkin's lymphoma
    Stephen M Ansell
    Mayo Clinic, Division of Hematology, 200 First Street SW, Rochester, MN 55905, USA
    Curr Opin Mol Ther 6:175-81. 2004
    ..Future studies will therefore be needed to explore the efficacy of combinations of these agents and to develop a rational strategy for their use...
  12. ncbi Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature
    Stephen M Ansell
    Division of Hematology Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Clin Lymphoma 5:202-4. 2004
    ....
  13. ncbi Adding cytokines to monoclonal antibody therapy: does the concurrent administration of interleukin-12 add to the efficacy of rituximab in B-cell non-hodgkin lymphoma?
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Lymphoma 44:1309-15. 2003
    ..However, a randomized controlled trial will be required to determine whether the addition of IL-12 adds to the efficacy of rituximab in B-cell NHL...
  14. pmc B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia
    Sherine F Elsawa
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905
    Blood 107:2882-8. 2006
    ..Furthermore, BLyS was found to increase the viability and proliferation of malignant B cells from WM patients. Due to the role of BLyS in WM, strategies to inhibit BLyS may potentially have therapeutic efficacy in these patients...
  15. doi Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 14:1105-10. 2008
    ..Atacicept (TACI-Ig), a recombinant fusion protein that inhibits both B-lymphocyte stimulator and a proliferation-inducing ligand, may be a novel treatment for B-cell malignancies...
  16. ncbi Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma
    Stephen M Ansell
    Division of Hematology, Mayo Clinic School of Medicine, Rochester, MN 55905, USA
    J Clin Oncol 25:2764-9. 2007
    ..To determine the safety, maximum-tolerated dose (MTD), and efficacy of MDX-060 in patients with relapsed or refractory CD30+ lymphomas, sequential phase I and II studies were performed...
  17. ncbi Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 99:67-74. 2002
    ..These data suggest that IL-12 and rituximab is an active combination and further studies of this combination in B-cell non-Hodgkin lymphoma are warranted...
  18. ncbi Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, Rochester, Minnesota and North Central Cancer Treatment Group, Rochester, Minnesota 55905, USA
    Clin Cancer Res 12:6056-63. 2006
    ..This phase II study was done to determine the efficacy and toxicity of IL-12 in combination with rituximab in patients with B-cell non-Hodgkin's lymphoma (NHL)...
  19. ncbi Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma
    Stephen M Ansell
    Divisions of Hematology and Nuclear Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 20:3885-90. 2002
    ..The goal of this analysis was to evaluate the therapy given to patients who relapsed after 90Y ibritumomab tiuxetan...
  20. ncbi Management of Hodgkin lymphoma
    Stephen M Ansell
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 81:419-26. 2006
    ..New therapies are clearly needed for these patients...
  21. doi Waldenström macroglobulinaemia: the key questions
    Anita D'Souza
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 162:295-303. 2013
    ..Diagnosis, prognosis, and indications for state-of-the-art therapy are updated. Current therapies presented at the 7th International Workshop for Waldenström Macroglobulinaemia are included. ..
  22. doi Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience
    Anita D'Souza
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 120:56-62. 2012
    ..Most patients could be salvaged with immunomodulatory drugs or radiation. The 5-year survival is 94%. Herein, we describe a system of monitoring response and progression among patients with POEMS after ASCT...
  23. pmc IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia
    Steven R Schuster
    Division of Hematology, Mayo Clinic Arizona, Scottsdale, AZ, USA
    Am J Hematol 85:853-5. 2010
    ..The subset of patients without lytic lesions or t(11;14) but with immunophenotypic features suggestive of MM need further study...
  24. pmc Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma
    M R Litzow
    Division of Hematology, Mayo Clinic Cancer Center, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Bone Marrow Transplant 45:490-7. 2010
    ..04). Topotecan can safely be dose escalated to 4.5 mg/m(2)/d in combination with CY, carboplatin and AHSCT. This trial is registered at ClinicalTrials.gov as NCT00652691...
  25. ncbi Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia
    M A Elliott
    Hematology Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Bone Marrow Transplant 37:1003-8. 2006
    ..Nevertheless, consistent with reported experience of others, overall outcomes remain less than optimal and unpredictable...
  26. ncbi Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma
    F K Buadi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Bone Marrow Transplant 37:1017-22. 2006
    ..The outcome may not be different from that of younger patients in terms of TRM and EFS...
  27. ncbi A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma
    A Dispenzieri
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leukemia 19:118-25. 2005
    ..Overall response rate was 94% including seven very good partial responses and five complete responses. Addition of 153Sm EDTMP to melphalan conditioning appears to be safe, well-tolerated and worthy of further study...
  28. ncbi Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate
    M A Gertz
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Bone Marrow Transplant 34:1025-31. 2004
    ..Methods are needed to reduce treatment-related toxicity so that more patients can receive full-dose conditioning chemotherapy...
  29. ncbi Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma
    L F Porrata
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 98:579-85. 2001
    ..In conclusion, ALC is correlated with clinical outcome and requires further study. (Blood. 2001;98:579-585)..
  30. pmc A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
    T E Witzig
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN 55905, USA
    Leukemia 25:341-7. 2011
    ..Everolimus has single-agent activity in relapsed/refractory aggressive NHL and provides proof-of-concept that targeting the mTOR pathway is clinically relevant...
  31. doi Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation
    L J Costa
    Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 41:715-20. 2008
    ..01). Patients with early, high IPI-R relapse after first-line therapy have a dismal outcome with SCT and should receive experimental therapies...
  32. ncbi Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma
    L F Porrata
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Bone Marrow Transplant 33:291-8. 2004
    ..0001, respectively). Multivariate analysis demonstrated A-ALC to be an independent prognostic indicator for OS and PFS. These data support our hypothesis that ALC-15 and survival are dependent upon the dose of infused A-ALC in NHL...
  33. pmc A role for IFN-lambda1 in multiple myeloma B cell growth
    A J Novak
    Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 22:2240-6. 2008
    ..Our data also show that IFN-lambda1 induces phosphorylation of STAT1, STAT3 and Erk. Taken together, our results suggest that IFN-lambda1 may regulate myeloma cell biology and could prove to be therapeutically important...
  34. doi Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma
    L F Porrata
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Leukemia 24:1343-9. 2010
    ..96 x 10(9)/l (N=46) (P<0.0001). This study suggests that lymphopenia measured by ALC can be used as a marker to assess risk of DLBCL relapse during routine follow-up after standard chemotherapy...
  35. pmc Molecular pathogenesis of Waldenstrom's macroglobulinemia
    Esteban Braggio
    Department of Hematology Oncology, Mayo Clinic in Arizona, 13400 East Shea Boulevard, Collaborative Research Building, Room 1 105, Scottsdale, AZ 85259 5494, USA
    Haematologica 97:1281-90. 2012
    ..In addition, the low number of in vitro or in vivo models significantly challenges extensive analysis. In this manuscript, we review the molecular basis of this disease...
  36. ncbi Interleukin 6 induces monocyte chemoattractant protein-1 expression in myeloma cells
    B K Arendt
    Department of Immunology, Mayo Graduate and Medical Schools, Mayo Clinic Foundation, Rochester, MN 55905, USA
    Leukemia 16:2142-7. 2002
    ....
  37. ncbi Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome
    S M Ansell
    Division of Hematology and Internal Medicine, Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 19:720-6. 2001
    ..This finding provides a strong rationale for the investigation of cellular immunotherapy in B-cell NHL...
  38. ncbi Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma
    R Howe
    Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester MN 55905, USA
    Bone Marrow Transplant 32:317-24. 2003
    ....
  39. ncbi A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors
    S M Ansell
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 91:1543-8. 2001
    ....
  40. pmc Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group
    David J Inwards
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Cancer 113:108-16. 2008
    ..The objective of this study was to test cladribine (2-CDA) alone and in combination with rituximab in patients with mantle cell lymphoma (MCL)...
  41. ncbi Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas
    Deepti Behl
    Division of Hematology Department Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Br J Haematol 137:409-15. 2007
    ..89 x 10(9)/l (5/39, 13%) (P < 0.0001). Multivariate analysis showed ALC to be an independent predictor for TTP. This study supports our hypothesis that a higher ALC predicts longer TTP following rituximab therapy...
  42. ncbi Stem cell transplantation for the management of primary systemic amyloidosis
    Morie A Gertz
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Med 113:549-55. 2002
    ..To review the characteristics and outcomes of amyloidosis patients treated with high-dose chemotherapy and stem cell reconstitution...
  43. ncbi Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone
    Lijo Simpson
    Division of Hematology, Department of Medicine, Rochester, MN, USA
    Leuk Lymphoma 48:1332-7. 2007
    ..Patients with progressive disease on DHAP should be considered for alternative salvage regimens or experimental therapy...
  44. pmc CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells
    Zhi Zhang Yang
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 110:2537-44. 2007
    ..Taken together, these studies reveal a novel role for NHL B cells in the development of intratumoral regulatory T cells...
  45. doi Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative
    Morie A Gertz
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:1131-8. 2008
    ..The overall 100-day survival rate was 98.9%. Our experience shows that outpatient transplant is feasible for all patients with multiple myeloma and results in shorter hospital stays and low treatment-related mortality rates...
  46. doi Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study
    Luis F Porrata
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Biol Blood Marrow Transplant 14:807-16. 2008
    ..This is the first study confirming the ALC-15 survival role prospectively and identifying NK cells as the key ALC-15 lymphocyte subset affecting survival after APHSCT...
  47. doi Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years
    Pankaj Malhotra
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 49:1724-30. 2008
    ..All surviving patients displayed excellent performance status without ongoing chronic graft versus host disease. We conclude that ASCT is an effective salvage therapy for fludarabine-refractory CLL but late relapses can occur...
  48. pmc Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma
    James R Cerhan
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 110:4455-63. 2007
    ....
  49. pmc Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era
    Thomas M Habermann
    Mayo Clinic College of Medicine, Rochester, MN, USA
    Blood 112:2694-702. 2008
    ..These data support a role for germ line variation in immune genes, particularly genes associated with a proinflammatory state, as predictors of late survival in DLBCL...
  50. pmc Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome
    Angela Dispenzieri
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Eur J Haematol 80:397-406. 2008
    ..Unraveling the mechanisms of the syndrome both in the context of ASCT and in general are challenges for the future...
  51. pmc Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group
    Stephen M Ansell
    Division of Hematology, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 113:508-14. 2008
    ..The objective of this study was to test a low dose of (25 mg weekly) of the mammalian target of rapamycin kinase inhibitor temsirolimus for patients with relapsed mantle cell lymphoma (MCL)...
  52. pmc Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival
    James R Cerhan
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 109:5439-46. 2007
    ..Common variation in host immune genes warrants further evaluation as a promising class of prognostic factors in follicular lymphoma...
  53. ncbi A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma
    Ivana N M Micallef
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer 107:2826-32. 2006
    ....
  54. ncbi Thalidomide treatment in myelofibrosis with myeloid metaplasia
    Michelle A Elliott
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Br J Haematol 117:288-96. 2002
    ..A lower dose of the drug might be more tolerable without compromising therapeutic value. Patients with PTMM and/or markedly increased circulating CD34+ cell counts might be susceptible to thalidomide-induced thrombocytosis...
  55. pmc Proteomic analysis of mantle-cell lymphoma by protein microarray
    Irene M Ghobrial
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 105:3722-30. 2005
    ..This study describes a novel technique that identifies proteins dysregulated in MCL...
  56. ncbi Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era
    Irene M Ghobrial
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Leuk Lymphoma 46:191-6. 2005
    ..004) and rituximab therapy (P = 0.03) were significant. Low IPI and rituximab therapy led to an improved overall survival in patients with CD20-positive PTLD...
  57. ncbi Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome
    Anne J Novak
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 104:2247-53. 2004
    ..In summary, we found that BLyS and its receptors represent a potentially important therapeutic target in B-cell lymphoma...
  58. ncbi Topotecan in patients with advanced neuroendocrine tumors: a phase II study with significant hematologic toxicity
    Stephen M Ansell
    Divisions of Hematology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
    Am J Clin Oncol 27:232-5. 2004
    ..In conclusion, further studies of this schedule of TOPA in this patient population are not recommended due to the lack of tumor response and significant hematologic toxicity...
  59. ncbi Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 104:1881-7. 2004
    ..Using this system, 49%, 38%, and 13% of patients were in stage I, stage II, and stage III, respectively. Determining levels of circulating biomarkers may be the most powerful tool for staging patients with AL undergoing PBSCT...
  60. ncbi Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma
    Irene M Ghobrial
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:318-25. 2004
    ..To assess the clinical relevance of chemokine receptor expression on the progression of B-cell chronic lymphocytic leukemia (B-CLL)...
  61. ncbi Therapeutic options in patients with lymphoma and severe liver dysfunction
    Irene M Ghobrial
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 79:169-75. 2004
    ....
  62. ncbi Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 103:3960-3. 2004
    ..Outside a randomized clinical trial, these results present the strongest data supporting the role of PBSCT in selected patients with AL...
  63. ncbi Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review
    Michelle A Elliott
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:421-30. 2003
    ..To assess the activity of von Willebrand factor-cleaving protease (vWF-CP) in patients with thrombotic thrombocytopenic purpura (TTP) complicating bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT)...
  64. ncbi Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease
    Luis F Porrata
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Br J Haematol 117:629-33. 2002
    ..5 x 10(9) cells/l ("not yet reached" versus 42 months, P < 0.0001; 57 versus 15 months, P < 0.002 respectively). Thus, ALC recovery on day 15 post ASCT in HD is associated with better survival and requires further study...
  65. ncbi Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia
    Ayalew Tefferi
    Mayo Clinic, Rochester, MN 55905, USA
    Blood 99:3854-6. 2002
    ..In vitro, imatinib mesylate caused variable degrees of growth suppression of myeloid and erythroid progenitors that unfortunately did not translate into clinical benefit...
  66. ncbi Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis
    Luis F Porrata
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Clin Cancer Res 11:1210-8. 2005
    ..The relationship of ALC-15 with clinical outcomes in primary systemic amyloidosis is unknown...
  67. ncbi Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
    Thomas E Witzig
    Mayo Clinic College of Medicine, Stabile 628, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 23:5347-56. 2005
    ..This study tested whether temsirolimus (previously known as CCI-779), an inhibitor of the mammalian target of rapamycin kinase that regulates cyclin D1 translation, could produce tumor responses in patients with MCL...
  68. ncbi The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphoma
    Yinlee Yoong
    Division of Hematology, Department of Internal Medecine, Mayo Clinic, Rochester, MN 55909, USA
    Leuk Lymphoma 46:1287-94. 2005
    ..0001). Multivariate analysis demonstrated K-ALC recovery post-ASCT to be an independent prognostic indicator for OS and PFS. These data support our hypothesis that the K-ALC post-ASCT is associated with clinical outcome in NHL...
  69. ncbi The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphoma
    Ivana N M Micallef
    Divison of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Lymphoma 47:1794-9. 2006
    ..In conclusion, tIPI at the time of histological transformation is an important predictor of OS. A time to transformation > 4 years from diagnosis is associated with better OS...
  70. ncbi Absolute lymphocyte count predicts overall survival in follicular lymphomas
    Mustaqeem Siddiqui
    Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA
    Br J Haematol 134:596-601. 2006
    ..677, P < 0.0001). These data suggest a critical role of FL patients' immune status at diagnosis on survival...
  71. pmc Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma
    Shernan G Holtan
    Division of Internal Medicine Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Br J Haematol 133:628-33. 2006
    ..0025, respectively). Multivariate analysis demonstrated TILC to be an independent prognostic indicator for OS and PFS. These findings suggest that the immune status of the host at the time of aphaeresis may predict survival after ASCT...
  72. ncbi An APRIL to remember: novel TNF ligands as therapeutic targets
    Stacey R Dillon
    Department of Autoimmunity and Inflammation, ZymoGenetics, Inc 1201 Eastlake Avenue East, Seattle, Washington 98102, USA
    Nat Rev Drug Discov 5:235-46. 2006
    ..Here we focus on APRIL, exploring its normal and pathological functions, and comparing the therapeutic molecules currently under development that target BLyS/BAFF alone, or APRIL and BLyS/BAFF together...
  73. ncbi Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders
    Anne J Novak
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 24:983-7. 2006
    ..Therefore, we sought to establish whether BLyS levels were elevated in patients with B-cell lymphoproliferative disorders and to determine whether elevated BLyS levels correlated with clinical characteristics of the disease...
  74. pmc Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Blood 107:3378-83. 2006
    ..Achievement of FLC response was a better predictor of survival than achievement of complete hematologic response or normalization of the FLC ratio. FLC measurements both before and after PBSCT are important predictors of patient outcome...
  75. ncbi Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma
    William G Martin
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 23:7614-20. 2005
    ..We reviewed our experience with BPT in HL to better delineate outcome and appropriate treatment in these patients...
  76. pmc Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma
    Zhi Zhang Yang
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 107:3639-46. 2006
    ..Taken together, our results suggest that T(reg) cells are highly represented in the area of B-cell NHL and that malignant B cells are involved in the recruitment of these cells into the area of lymphoma...
  77. pmc Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma
    Zhi Zhang Yang
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 66:10145-52. 2006
    ..Taken together, these data indicate that human lymphoma B cells are sensitive to autologous CTL-mediated cell death but are protected by the inhibitory function of intratumoral T(reg) cells...
  78. ncbi Primer on medical genomics. Part III: Microarray experiments and data analysis
    Ayalew Tefferi
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 77:927-40. 2002
    ..The current review should serve as an introduction to the subject for clinician investigators, physicians and medical scientists in training, practicing clinicians, and other students of medicine...
  79. ncbi Primer on medical genomics. Part VI: Genomics and molecular genetics in clinical practice
    Stephen M Ansell
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:307-17. 2003
    ....
  80. ncbi Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders
    Irene M Ghobrial
    Division of Hematology, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, 200 First St, SW, Rochester, MN 55905, USA
    J Clin Oncol 23:7574-82. 2005
    ..The objective of this study was to determine prognostic factors for overall survival in patients with post-transplantation lymphoproliferative disorders (PTLDs)...
  81. doi The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma
    Dimitrios Karantanis
    Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Lymphoma Myeloma 8:94-9. 2008
    ..The purpose of this study was to assess the value of FDG PET/CT in this aggressive type of non-Hodgkin lymphoma...
  82. ncbi Efficacy and treatment-related toxicity of radiotherapy for early-stage primary non-Hodgkin lymphoma of the parotid gland
    Kenneth R Olivier
    Division of Radiation Oncology, Mayo Clinic, Rochester, MN, USA
    Int J Radiat Oncol Biol Phys 60:1510-4. 2004
    ..To assess the efficacy of radiotherapy (RT) in the treatment of primary non-Hodgkin lymphoma (NHL) of the parotid gland...
  83. pmc Selective activation of TACI by syndecan-2
    Daniela Bischof
    Mayo Clinic, Mayo Medical School, Department of Pediatric and Adolescent Medicine, Rochester, MN 55905, USA
    Blood 107:3235-42. 2006
    ..This is the first identification of ligands that selectively activate TACI without simultaneously triggering BCMA or BAFF-R. This finding may help explain the alternative outcomes of signaling from this family of receptors in B cells...
  84. ncbi Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases?
    Irene M Ghobrial
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street, Rochester, MN 55905, USA
    Transplantation 79:244-7. 2005
    ....

Research Grants9

  1. Biologic therapy for Beta-cell non-Hodgkin's lymphoma
    Stephen Ansell; Fiscal Year: 2005
    ..abstract_text> ..
  2. BLys inhibition using TACI-Fc in patients with B-bell non-Hodgkins' Lymphoma
    Stephen Ansell; Fiscal Year: 2007
    ....
  3. Biologic Therapy for B-cell non-Hodgkin's Lymphoma
    Stephen M Ansell; Fiscal Year: 2010
    ..This treatment combination will lead to a novel therapeutic approach to modulating Treg cells that will result in clinical benefit for patients with B-cell NHL. ..